Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
株式のランク #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
株価
$193.62
時価総額
$150.08B
変化(1日)
2.76%
変化(1年)
184.69%
GB
取引 AstraZeneca PLC (AZN)

カテゴリー

AstraZeneca PLC(AZN)の配当履歴
AstraZeneca PLC(証券コード:AZN)は合計で67回の配当を行いました。
すべての配当の合計(株式分割調整済み)は:$33.24
配当利回り(TTM):0.0161
1993から2026までのAstraZeneca PLC(AZN)の配当履歴
年間配当支払い
配当(株式分割調整済み) 変化
2026 (TTM) $2.17 38.88%
2025 $1.57 6.10%
2024 $1.48 1.72%
2023 $1.45 0.00%
2022 $1.45 3.57%
2021 $1.40 0.00%
2020 $1.40 0.00%
2019 $1.40 0.00%
2018 $1.40 0.00%
2017 $1.40 0.00%
2016 $1.40 0.00%
2015 $1.40 0.00%
2014 $1.40 0.00%
2013 $1.40 -1.75%
2012 $1.43 5.56%
2011 $1.35 12.03%
2010 $1.21 15.31%
2009 $1.05 10.00%
2008 $0.95 8.57%
2007 $0.875 24.11%
2006 $0.705 37.56%
2005 $0.5125 22.75%
2004 $0.4175 7.46%
2003 $0.3885 -0.13%
2002 $0.389 0.00%
2001 $0.389 -57.97%
2000 $0.9255 205.45%
1999 $0.303 -23.77%
1998 $0.3975 11.38%
1997 $0.3569 44.49%
1996 $0.247 -13.97%
1995 $0.2871 10.47%
1994 $0.2599 169.33%
1993 $0.0965 0.00%
すべての配当支払いの一覧
配当 変化
2026 (TTM) $2.17 38.88%
2025 $1.57 6.10%
2024 $1.48 3.15%
2023 $1.43 0.70%
2022 $1.42 2.16%
2021 $1.39 0.00%
2020 $1.39 -0.71%
2019 $1.40 0.00%
2018 $1.40 0.00%
2017 $1.40 0.00%
2016 $1.40 -40.43%
2015 $2.35 -16.07%
2014 $2.80 0.00%
2013 $2.80 -1.75%
2012 $2.85 5.56%
2011 $2.70 12.03%
2010 $2.41 15.31%
2009 $2.09 10.00%
2008 $1.90 8.57%
2007 $1.75 24.11%
2006 $1.41 37.56%
2005 $1.03 22.75%
2004 $0.835 7.46%
2003 $0.777 -0.13%
2002 $0.778 0.00%
2001 $0.778 -57.97%
2000 $1.85 205.45%
1999 $0.606 -66.68%
1998 $1.82 -15.04%
1997 $2.14 44.47%
1996 $1.48 -13.99%
1995 $1.72 10.52%
1994 $1.56 169.26%
1993 $0.579 0.00%
同業他社や競合企業の配当履歴
企業 配当支払い回数
215.00%
US
225.00%
US
53.00%
US
32.00%
CH
223.00%
US